Search results for "Bempedoic acid"

showing 4 items of 4 documents

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia

2020

Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.

bempedoic acidmedicine.medical_specialtyStatinmedicine.drug_classHyperlipidemiasFamilial hypercholesterolemia030204 cardiovascular system & hematologyLipid-lowering therapystatins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansDicarboxylic AcidsIn patient030212 general & internal medicineHypolipidemic AgentsClinical Trials as Topiclipid-lowering therapyCholesterolbusiness.industryFatty Acidsnutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaselow-density lipoproteinchemistryDrug Therapy Combinationlipids (amino acids peptides and proteins)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsatherosclerosisCardiology and Cardiovascular MedicinebusinessBempedoic acidLipoproteinCoronary Artery Disease
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct